F
Federico A Monzon
Publications - 5
Citations - 165
Federico A Monzon is an academic researcher. The author has contributed to research in topics: Sentinel lymph node & Cutaneous melanoma. The author has an hindex of 3, co-authored 5 publications receiving 103 citations.
Papers
More filters
Journal ArticleDOI
Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients
Adam C. Berger,Robert S. Davidson,J. Kevin Poitras,Indy Chabra,Richard Hope,Amy Brackeen,Clare Johnson,Derek Maetzold,Brooke Middlebrook,Kristen M. Oelschlager,Robert W. Cook,Federico A Monzon,Alexander R Miller +12 more
TL;DR: Molecular risk classification by gene expression profiling has clinical impact and influences physicians to direct clinical management of CM patients, and the vast majority of the changes implemented after the receipt of test results were reflective of the low or high recurrence risk associated with the patient's molecular classification.
Journal ArticleDOI
Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling.
John T. Vetto,Eddy C. Hsueh,Brian R. Gastman,Larry D Dillon,Federico A Monzon,Robert W. Cook,Jennifer Keller,Xin Huang,Andrew M. Fleming,Preston Hewgley,Pedram Gerami,Sancy A. Leachman,Jeffrey D. Wayne,Adam C. Berger,Martin D. Fleming +14 more
TL;DR: The 31-gene expression profile test identifies patients who could potentially avoid SLN biopsy and identifies patients with T1-T2 melanoma at low risk for sentinel lymph node positivity.
Journal ArticleDOI
Prospective, Multicenter Clinical Impact Evaluation of a 31-Gene Expression Profile Test for Management of Melanoma Patients
Larry D Dillon,Joseph E Gadzia,Robert S. Davidson,Michael McPhee,Kyle R. Covington,Robert W. Cook,Clare Johnson,Federico A Monzon,Eric D Milanese,John T. Vetto,Abel D Jarell,Martin D. Fleming +11 more
TL;DR: Physicians used test results to guide risk-appropriate changes that match the biological risk of the tumor, including directing more frequent and intense surveillance to high-risk, Class 2 patients.
Journal ArticleDOI
Integrating 31-Gene Expression Profiling With Clinicopathologic Features to Optimize Cutaneous Melanoma Sentinel Lymph Node Metastasis Prediction.
Eric D. Whitman,Vadim P. Koshenkov,Brian R. Gastman,Deri Lewis,Eddy C. Hsueh,Ho Pak,Thomas P. Trezona,Robert S. Davidson,Michael McPhee,J. Michael Guenther,Paul Toomey,Franz O. Smith,Peter D. Beitsch,James M. Lewis,Andrew Ward,Shawn E. Young,Parth K. Shah,Ann P. Quick,Brian Martin,Olga Zolochevska,Kyle R. Covington,Federico A Monzon,Matthew S. Goldberg,Robert W. Cook,Martin D. Fleming,David M Hyams,John T. Vetto +26 more
TL;DR: In this paper, sentinel lymph node biopsy (SLNB) was recommended for patients with > 10% likelihood of positive sentinel node positivity, but the guidelines do not rec...
Journal ArticleDOI
Improvement of risk assessment in cutaneous melanoma (CM) by a prognostic 31-gene expression profile (31-GEP) test over AJCC-based staging alone
TL;DR: The objective was to establish an experimental procedure and show direct results that unequivocally can be assigned as a “safe and effective” treatment for central giant cell granuloma.